Clinical Trial Update: Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and tolerability of dostarlimab in combination with antiretroviral therapy for refractory HIV-associated Kaposi sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kaposi Sarcoma

Drugs mentioned

• Dostarlimab (dostarlimab)

Snippet

Sponsor: Imperial College London | Conditions: Refractory HIV Associated Kaposi Sarcoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING